Cavizid: an anti-tuberculosis drug from India
Cavizide (international name pyrazinamide) is an anti-tuberculosis drug produced in India by Tata Pharma. It belongs to the group of anti-tuberculosis drugs of different chemical groups.
The dosage form of Cavizide is tablets containing 500 mg of the active substance - pyrazinamide. This drug is used to treat tuberculosis.
Like any drug, Cavizid has its contraindications and side effects. Contraindications to the use of Cavizide include hypersensitivity to the drug, liver dysfunction and acute gout. Side effects may include fever, porphyria, interstitial nephritis and dysuria, liver damage, anorexia, dyspeptic symptoms, arthralgia, myalgia, increased serum iron concentrations, a tendency to thrombus formation and allergic reactions.
Interaction of Cavizide with other anti-tuberculosis drugs may enhance their effects, and with drugs used to treat gout, reduce their effectiveness.
There is no information about overdose and special instructions for the use of Cavizid.
Overall, Cavizide is an effective anti-tuberculosis drug, but it should only be taken under medical supervision and as recommended to avoid possible side effects and ensure maximum effectiveness of treatment.